Traditional drug discovery methods often rely on animal models or simplistic cell cultures that fail to accurately replicate human tissue complexity and microenvironment. This leads to inaccurate predictions of drug distribution and efficacy, resulting in costly late-stage failures in clinical trials.

VoxCell develops bioprinted tissue models that mimic human tissue structures, including advanced vasculature, to provide more predictive drug distribution and efficacy data during preclinical trials. Their platform utilizes customizable bioinks and in-house software to generate human-like vessel models tailored to specific research needs. By screening candidate compounds in these tissue models, researchers can obtain translatable data that enhances the accuracy of therapeutic assessments and accelerates the preclinical pathway.

Customizable bioinks designed to replicate the extracellular matrix of soft living tissues

Generation of advanced, human-like vasculature within bioprinted tissue models

In-house software for designing and optimizing vessel structures

Screening assays to evaluate drug distribution and efficacy in a human-relevant context

Predictive data that reduces the risk of late-stage clinical trial failures

The primary target audience includes pharmaceutical companies, biotechnology firms, and academic research institutions involved in preclinical drug discovery and development.